Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jun;95(24):e3513.
doi: 10.1097/MD.0000000000003513.

The diagnostic performance of serum MUC5AC for cholangiocarcinoma: A systematic review and meta-analysis

Ji Xuan  1 , Jing Li, Zhirui Zhou, Renrong Zhou, Huabing Xu, Wei Wen
Affiliations
Meta-Analysis

The diagnostic performance of serum MUC5AC for cholangiocarcinoma: A systematic review and meta-analysis

Ji Xuan et al. Medicine (Baltimore). 2016 Jun.

Erratum in

Abstract

Specific diagnostic biomarker for cholangiocarcinoma (CCA) has been lacking. This systematic review and meta-analysis was performed aiming to investigate serum MUC5AC's diagnostic performance on CCA.Studies investigating serum MUC5AC's diagnostic value on CCA were retrieved from Pubmed, Embase, and Cochrane Library. The methodology quality of included studies was assessed according to QUADAS-2. Diagnostic 2 × 2 table was extracted from each eligible study, Meta-disc 1.4 was used for statistical analysis, data synthesis was done using a random-effects model. Subgroup analyses were conducted according to region and array method.Six eligible studies were identified, a total of 1213 patients were involved in the meta-analysis. The AUC on SROC was 0.9138, and the Q* was 8463. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio (DOR) were 0.69 (95% CI: 0.65-0.73), 0.93 (95% CI: 0.91-0.95), 8.99 (95% CI: 5.65-14.30), 0.33 (95% CI: 0.24-0.46), and 33.98 (95% CI: 20.12-57.40), respectively. Targeting MUC5AC's epitope has a higher pooled sensitivity than targeting MUC5AC protein (0.77 vs 0.63). There was substantial cross-study heterogeneity.Serum MUC5AC might be potentially used as a surrogate marker in the diagnosis of CCA. However, the appropriate array method and the optimum cut-off value are yet to be decided.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart illustrating literature search and screening.
Figure 2
Figure 2
MUC5AC's overall diagnostic performance on CCA. A, SROC. B, Pooled DOR. AUC, area under curve; CI, confidence interval; df, degrees of freedom; SE, standard error.
Figure 3
Figure 3
Pooled sensitivity and specificity of serum MUC5AC for CCA. A, Pooled sensitivity. B, Pooled specificity. CI, confidence interval; df, degrees of freedom.
Figure 4
Figure 4
Pooled positive likelihood ratio and negative likelihood ratio of serum MUC5AC for CCA. CI, confidence interval; df, degrees of freedom.
See this image and copyright information in PMC

References

    1. Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 2006;23:1287–96. - PubMed
    1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013;145:1215–29. - PMC - PubMed
    1. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004;24:139–54. - PubMed
    1. Sasaki M, Tsuneyama K, Nakanuma Y. Aberrant expression of trefoil factor family 1 in biliary epithelium in hepatolithiasis and cholangiocarcinoma. Lab Invest 2003;83:1403–13. - PubMed
    1. Park SY, Roh SJ, Kim YN, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep 2009;22:649–57. - PubMed

MeSH terms